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Description of the subject: Triple-negative breast cancer (TNBC), a breast cancer subtype, is characterized 
by the lack of both estrogen and progesterone hormonal receptors expression and by the absence of human 
epidermal growth factor receptor 2 overexpression. Patients with a pathological complete response (pCR) 
have better disease-free and overall survival compared to those with residual disease. The high level of tumor-
infiltrating lymphocytes (TILs) is associated with a higher response to neoadjuvant chemotherapy (NAC) and 
better prognosis. 
Objective: Evaluation of TILs and their predictive impact in early TNBC in an Algerian population.  
Methods: We assessed TILs and correlated them with the pCR rate in 94 early TNBC patients treated from 
2015 to 2017 who underwent breast microbiopsy, NAC, and then surgery.  
Results: Among 94 early TNBC patients, 53 (56.4%) achieved pCR and 41 (43.6%) had a residual disease. 
While some clinicopathological factors did not affect pCR, stromal TILs showed significant correlation with 
pCR (P < 0.0001). The presence of CD3+, CD4+, CD8+ and CD20+ TILs was also significantly correlated with 
pCR (P < 0.0001, P = 0.001, P = 0.0003 and P = 0.0001, respectively).  
Conclusion: Our data showed that TILs were significantly associated with pCR, suggesting that TILs are 
a predictive biomarker for pCR in early TNBC patients treated by NAC in our cohort.  
Key words: triple-negative breast cancer, pathological complete response, tumor-infiltrating lymphocytes, 





Opis teme: Trostruko negativni rak dojke (TNBC), podtip raka dojke, okarakteriziran je izostankom 
ekspresije hormonalnih receptora i estrogena i progesterona te izostankom prekomjerne ekspresije receptora 
epidermalnog čimbenika rasta 2. Bolesnice s kompletnim patološkim odgovorom (pCR) imaju bolje 
preživljavanje bez bolesti i općenito preživljavanje u usporedbi s onima s rezidualnom bolešću. Visoka razina 
tumor-infiltrirajućih limfocita (TIL-i) povezana je s boljim odgovorom na neoadjuvantnu kemoterapiju (NAC) 
i s boljom prognozom.  
Cilj: Procijeniti TIL-e i njihov predvidivi učinak na rani TNBC u populaciji u Alžiru. 
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Metode: Procijenili smo TIL-e i korelirali ih s postotkom pCR-a u 94 bolesnica s ranim TNBC liječenih 
od 2015. do 2017. godine, koje su bile podvrgnute mikrobiopsiji dojki, neoadjuvantnoj kemoterapiji i potom 
operativnom zahvatu. 
Rezultati: Među 94 bolesnice s ranim TNBC, 53 njih (56,4 %) postiglo je pCR, a 41 (43,6 %) je imala 
rezidualnu bolest, dok neki kliničko-patološki čimbenici nisu utjecali na pCR, stromalni TIL-i pokazali su 
značajnu korelaciju s pCR-om (P < 0,0001). Prisutnost CD3+, CD4+, CD8+ i CD20+ TIL-a značajno je 
korelirala i s pCR-om (P < 0,0001, P = 0,001, P = 0,0003, odnosno P = 0,0001).  
Zaključak: Naši podaci pokazali su da su TIL-i značajno povezani s pCR-om, što navodi na zaključak da 
su TIL-i prediktivni biomarker za pCR u bolesnica s ranim TNBC liječenima neoadjuvantnom kemoterapijom 
u našoj kohorti. 
Ključne riječi: trostruko negativni rak dojke, patološki potpuni odgovor, limfociti koji infiltriraju tumor, 






Triple-negative breast cancer (TNBC) is a breast 
cancer subgroup characterized by the lack of 
expression of human epidermal growth factor receptor 
2 (HER2), progesterone receptor (PR) and estrogen 
receptor (ER) assessed by immunohistochemistry 
(IHC). It represents 15% to 20% of breast carcinomas.1 
TNBC is a type of breast cancer that affects younger 
women more often, and generally has a worse 
prognosis than other types of breast cancer.2 This 
subtype is usually aggressive, poorly differentiated, 
and is characterized by a high mitotic index.1 TNBC is 
heterogeneous in terms of molecular profile. Lehmann 
et al.3 evaluated the gene expression profiles of 587 
TNBC. Six molecular subtypes have been identified 
including 2 basal-like, a mesenchymal, a mesenchymal 
stem-like, an immunomodulatory, and a luminal 
androgen receptor subtype. For each molecular subtype, 
treatment sensitivity varies from a subtype to another. 
Nowadays, neoadjuvant chemotherapy (NAC) is 
considered as the standard care in early TNBC.4 In 
early breast cancer, patients who achieved a 
pathological complete response (pCR) after NAC tend 
to have improved survival compared to patients with 
residual disease.5  
Both innate and adaptive immunity play a principal 
role in the immune surveillance against cancer and can 
limit cancer progression.6 Previous research has shown 
that stromal TILs were an independent predictive and 
prognostic biomarker of outcome in early TNBC.7 
Studies have explored the predictive and prognostic 
value of TILs subsets in early breast cancer. For 
instance, previous studies have shown that the 
increased infiltration of CD3+ and CD20+ TILs has 
significantly predicted pCR.8,9 Other studies have also 
revealed that CD4+ and CD8+ TILs were found to be 
predictive of pCR9,10 and had a favorable prognostic 
value.11 
In our research, we assessed TILs and their impact 
on pCR rate in early TNBC in Algerian patients.  




The study cohort included 94 patients treated for 
stage I-III breast cancer from 2015 to 2017 in Pierre 
and Marie Curie Cancer Center (CPMC) in Algiers-
Algeria. All patients had a core microbiopsy confirming 
a TNBC subtype. They received NAC based on 3 
cycles; combining docetaxel and carboplatin every 
three weeks followed by three-cycle-anthracycline-
based chemotherapy. The study was performed 
according to the ethical recommendations of the 
Helsinki declaration. An informed and written consent 
dated and signed by the patients was accordingly 
obtained by our ethical committee.  
 
Clinicopathological factors assessment  
 
The assessed clinicopathologic factors included: 
patients’ age at diagnostic, tumor stage, nodal status, 
tumor-node-metastasis (TNM) stage, histological type, 
histological grade, biomarkers (ER, PR, HER2 and      
Ki-67 proliferation index), and histopathological 
response. Tumor stage, nodal status, and TNM stage 
were clinically evaluated using pre-treatment images 
in compliance with the Union for International Cancer 
Control TNM classification.12 As for the histological 
type, the histological grade, as well as the biomarkers, 
were determined using pre-therapeutic microbiopsies 
specimens. Histological types were defined as per the 
WHO classification.13 While the histological grade 
was assessed using the Scarff, Bloom and Richardson 
method,14 IHC of ER and PR was performed using ER 
antibodies (clone SP1, ready-to-use, Ventana) and PR 
antibodies (clone 1E2, ready-to-use, Ventana). The ER 
and PR expression was assessed by the Allred 
Immunohistochemistry Score.15 Concerning the HER2 
expression, it was performed using a HER2 antibody 
(clone 4B5, ready-to-use, Ventana). HER2 2+ cases 
were analyzed by dual in situ hybridization using an 
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INFORM HER2 Dual ISH DNA Probe Cocktail 
(Ventana). HER2 expression and in situ hybridization 
were both assessed following the American Society of 
Clinical Oncology (ASCO)/College of American 
Pathologists (CAP) guidelines for HER2 testing.16 The 
Ki-67 proliferation index was evaluated by IHC using 
a Ki-67 antibody (clone 30-9, ready-to-use, Ventana). 
The result was given in percentage. All the four-
marker-analysis was carried out on the Ventana 
BenchMark ULTRA automated platform (BenchMark 
ULTRA automates, UltraView Universal DAB 
Detection Kit, Ventana Medical Systems; Tucson, AZ, 
USA).  
In our study, the pCR was defined as a non-residual 
invasive tumor in both the breast and the axillary 
lymph nodes, based on the histopathological 
evaluation of the resection specimen after NAC. 
Residual carcinoma in situ was included in the pCR 
(ypT0/Tis ypN0). 
 
Tumor-infiltrating lymphocytes assessment  
 
Pre-therapeutic core microbiopsies were formalin-
fixed and paraffin-embedded. Thin sections were cut 
and stained with hematoxylin and eosin (H&E). 
Stromal TILs evaluation was performed on H&E 
sections on core microbiopsies. Stromal TILs were 
defined as mononuclear cells localized in the stroma 
surrounding carcinoma cells and were assessed 
according to international TILs working group 
guidelines (stromal TILs were defined as the 
percentage of tumor stroma area infiltrated by 
lymphocytes).17 Regarding the evaluation of stromal 
TILs subpopulations, formalin-fixed and paraffin-
embedded sections of core microbiopsies were stained 
using an IHC method. The following antibodies were 
used on IHC analysis: CD3 (IR503 polyclonal 
antibody, ready-to-use, Dako), CD4 (clone 4B12, 
ready-to-use, Dako), CD8 (clone C8/144B, ready-to-
use, Dako) and CD20 (clone L26, ready-to-use, Dako). 
The analysis of all these markers was carried out under 
the Ventana BenchMark ULTRA automated platform 
(BenchMark ULTRA automates, UltraView Universal 
DAB Detection Kit, Ventana Medical Systems; 
Tucson, AZ, USA). TILs subsets were reported as the 
percentages of tumor stroma area infiltrated by cells 
positive for CD3, CD4, CD8, and CD20.  
In this study, a semi-quantitative scoring method 
was utilized to evaluate the density of stromal TILs and 
TILs subsets. We categorized the findings into three 
groups: low (score: 0-10%), intermediate (score: 11-




All clinicopathological factors (age at diagnosis, 
tumor stage, nodal status, TNM stage, histological 
type, Ki-67 proliferation index, histological grade, 
stromal TILs and TILs subsets) were compared 
between the pCR and non-pCR groups. The 
relationship between clinicopathological factors and 
pCR was determined using the chi-squared test for 
categorical variables and the Welch t-test for 
continuous variables. A P value < 0.05 was considered 
statistically significant. The calculations were 






Patients’ clinicopathological characteristics are 
shown in Table 1. The mean and median age was 40.8 
± 9.528 years and 38.5 years, respectively (range, 22-
64 years). Most patients were diagnosed with T2 (31.9%) 
and T3 (41.5%) tumors, whereas T1 and T4 diseases 
were seen in only 1.1% and 25.5% respectively.  
The axillary lymph nodes metastasis was present in 
60.6%. In terms of the TNM stage, only one case 
(1.1%) was classified as stage I, 47 cases (50%) as stage 
II, and 46 cases (48.9%) as stage III. Invasive ductal carci-
noma was the predominant histological type (97.9%).  
The mean rate of the Ki-67 proliferation index was 
61.82 ± 22.95% (range, 10-90%). The histological 
grade was grade II in 36 cases (38.3%) and grade III in 
58 cases (61.7%). Among 94 patients, 56.4% (54 
patients) achieved pCR, whereas 43.6% (41 patients) 
still had residual disease.  
As far as stromal TILs are concerned, 19 cases 
(20.2%) had low TILs, 50 cases (53.2%) had 
intermediate TILs and 25 cases (26.6%) had high TILs.  
For stromal CD3+ TILs, 19 cases (20.2%) had low 
CD3+ TILs, 54 cases (57.5%) had intermediate CD3+ 
TILs and 21 cases (22.3%) had high CD3+ TILs. When 
it comes to stromal CD4+ TILs, 43 cases (45.7%) had 
low CD4+ TILs, 48 cases (51.1%) had intermediate 
CD4+ TILs and 3 cases (3.2%) had CD4+ high TILs. 
For stromal CD8+ TILs, 31 cases (33%) had low CD8+ 
TILs, 53 cases (56.4%) had intermediate CD8+ TILs 
and 10 cases (10.6%) had high CD8+ TILs. Finally, 
stromal CD20+ TILs, 72 cases (76.6%) had low CD20+ 
TILs and 22 cases (23.4%) had intermediate CD20+ 
TILs. No high CD20+ TILs infiltrate was seen.  
Representative microphotographs showing different 
stromal TILs densities by H&E and IHC staining in the 
examined pre-therapeutic microbiopsies specimens are 
shown in Pictures 1 and 2.
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Table 1 Clinicopathological factors of all patients 




Number of patients No. (%) 
Broj bolesnika (n = 94) 
Age at diagnosis (years) / Dob na dijagnozi (godine) 
Mean ± SD/ Srednje ± SD 
Range/ Domet 
 
40.8 ± 9.528 
22-64 










Nodal status / Nodalni status 
Negative / Negativan 












Histological type / Histološki tip 
Ductal / Duktalni 




Ki-67 proliferation index / Indeks proliferacije Ki-67 (%) 
Mean ± SD / Srednje ± SD 
Range / Domet 
 
61.82 ± 22.95 
10-90 






Histopathological response / Histopatološki odgovor 
pCR 





Low / Nisko 
Intermediate / Srednje 





Stromal CD3+ TILs 
Low / Nisko 
Intermediate / Srednje 





Stromal CD4+ TILs 
Low / Nisko 
Intermediate / Srednje 





Stromal CD8+ TILs 
Low / Nisko 
Intermediate / Srednje 





Stromal CD20+ TILs 
Low / Nisko 




SD: standard deviation, TNM: tumor-node-metastasis, pCR: pathological complete response, TILs: tumor-infiltrating 
lymphocytes./ SD: standardna devijacija, TNM: metastaza u tumoru-čvoru, pCR: potpuni patološki odgovor, TIL: limfociti 
koji infiltriraju tumor. 





Picture 1 Representative microphotographs of stromal TILs according to TILs density (H&E staining, x200). 
(a) Low TILs, (b) Intermediate TILs, (c) High TILs. T: tumor; S: stroma. 
Slika 1. Reprezentativne mikrofotografije stromalnih TILs prema gustoći TILs (bojanje H&E, x200). (a) Niski 






Picture 2 Immunohistochemical staining of stromal TILs (x400). (a) Low CD3+ TILs, (b) Intermediate CD3+ 
TILs, (c) High CD3+ TILs, (d) Low CD8+ TILs, (e) Intermediate CD8+ TILs, (f) High CD8+ TILs. 
Slika 2. Imunohistokemijsko bojanje stromalnih TIL-ova (x400). (a) Niski CD3 + TIL, (b) Srednji CD3 + TIL, 
(c) CD3 + TIL, (d) Niski CD8 + TIL, (e) Srednji CD8 + TIL, (f) Visoki CD8 + TIL. 
 
 
The relationship between clinicopathological 
factors and pCR  
 
All parameters, including patients’ age at 
diagnostics, tumor stage, nodal status, TNM stage, 
histological type, Ki-67 proliferation index, 
histological grade, stromal TILs and TILs subsets, 
were compared between the pCR and non-pCR groups 
(Table 2).  
There was no significant relationship between pCR 
and age at diagnosis (P = 0.341), tumor stage (P = 
0.371), nodal status (P = 0.562), TNM stage (P = 
0.856), histological type (P = 1), Ki-67 proliferation 
index (P = 0.806) and histological grade (P = 0.200). 
Increased infiltration of stromal TILs was 
significantly associated with pCR (P < 0.0001). A 
significant association was found between pCR and 
higher pre-NAC infiltration by stromal CD3+ T cells (P 
< 0.0001), stromal CD4+ T cells (P = 0.001), stromal 
CD8+ T cells (P = 0.0003) and stromal CD20+ B cells 








a b c 
 
d 
a b c 
 
d e f 
 
S 
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Table 2 Comparison of responding and non-responding patients’ clinicopathological factors 
Tablica 2. Usporedba kliničko patoloških čimbenika pacijenata koji reagiraju i koji ne reagiraju  
 
Clinicopathological factors 
Kliničko patološki čimbenici 
pCR (n = 53) 
No. (%) 
Non-pCR No. (%) 
Nije pCR (n = 41) 
P Value  
P Vrijednost 
Age at diagnostic (years) / Dob na dijagnostici (godine) 
Mean ± SD / Srednje ± SD 
39.96 ± 9.19 41.88 ± 9.958 0.341 










Nodal status / Nodalni status 
Negative / Negativan 


















Histological type / Histološki tip 
Ductal / Duktalni  








Ki-67 proliferation index / Indeks proliferacije Ki-67 (%) 
Mean ± SD / Srednje ± SD 
Range / Domet 
62.34 ± 21.99 61.15 ± 24.41 0.806 
Histological grade /  Histološka ocjena 









Stromal TILs  
Low / Nisko 
Intermediate / Srednje 










Stromal CD3+ TILs 
Low / Nisko 
Intermediate / Srednje 










Stromal CD4+ TILs 
Low / Nisko 
Intermediate / Srednje 










Stromal CD8+ TILs 
Low / Nisko 
Intermediate / Srednje 










Stromal CD20+ TILs 
Low / Nisko 









pCR: pathological complete response, SD: standard deviation, TNM, tumor-node-metastasis, TILs: tumor- infiltrating 
lymphocytes / pCR: potpuni patološki odgovor, SD: standardna devijacija, TNM, metastaza tumorskih čvorova, TIL: 




To our knowledge, this is the first publication 
evaluating lymphocytic infiltrate and its impact on pCR 
in Algerian patients treated for early TNBC. This study 
differs from previous investigations in that it classified 
TILs into three groups, to get a clearer comprehension of 
their relationship with the response to NAC.  
The development of cancer cells is characterized by 
interactions of tumor cells with the tumor micro-
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environment, such as tumor-infiltrating immune cell 
populations.18 In the TNBC case, infiltrated immune 
cells are found in up to 75% of tumor, with up to 20% 
of the tumor having an especially high infiltration.19 
In our study, we found out that increased levels of 
stromal TILs showed a significantly higher pCR rate. 
Similar to our findings, the GeparSixto study has 
shown that stromal TILs were independently and 
significantly associated with a high pCR rate in early 
TNBC.20 Besides, the role of stromal TILs in different 
subsets of breast cancer was stressed by Denkert et al.7 
reporting that as an immunological marker, stromal 
TILs were an independent predictor of pCR in all 
breast cancer subtypes (triple-negative, HER2-positive, 
and luminal-HER2-negative early breast cancer) and 
were also associated with a favorable prognosis in 
triple-negative and HER2-postive early breast cancer.  
The impact of TILs subsets on response to NAC is 
less explored in early TNBC and there are only limited 
studies that have investigated the relationship between 
some TILs subsets and pCR in purely early TNBC 
cohorts.  
What was noticed was that the high level of stromal 
CD3+ TILs was significantly associated with a high 
pCR rate. In the tumor microenvironment, TILs tend 
to be mainly CD3+ T lymphocytes,21 and the majority 
are CD3+/CD8+ T lymphocytes.22,23 Previous 
investigations have shown that stromal CD3+ TILs 
were found to be a predictive factor for pCR.8-10  
Our study also revealed that stromal CD4+ TILs 
were significantly associated with a high pCR rate. 
Previous studies have shown that CD4+ TILs indicated 
a good response to NAC and a favorable prognosis in 
early breast cancer patients. For instance, one study has 
shown that the presence of stromal CD4+ TILs had an 
independent predictive value for pCR.10 Further 
studies have suggested that a high level of CD4+ T cells 
in the breast tumors was a good prognostic 
indicator.11,24 CD4 is expressed in many T cell subsets 
including T helper 1 cells, T helper 2 cells, T helper 17 
cells, regulatory T cells, and T follicular helper cells, 
each of which may have a different role on pCR and 
prognosis. T helper 1 (Th1) cells involved in the 
antitumor immune response support CD8+ T 
lymphocytes by secreting interferon-γ and interleukin-
2.25 Gu-Trantien et al.21 reported that Th1 subset was 
associated with a better response to NAC in all breast 
cancer subgroups assessed (ER-negative/HER2-
negative, ER-positive/HER2-negative, and HER2-
positive early breast cancer) and with a good prognosis 
in patients with early HER2-positive breast cancer. The 
presence of Treg cells was linked with both bad and 
good.26-28 Oda et al.29 demonstrated that the presence 
of large numbers of intratumoral Treg cells into pre-
therapeutic biopsy specimens of early breast cancer 
patients was an independent predictive factor for pCR. 
Th17 cells appear to have both antitumor and protumor 
effects.25 In a study on early breast cancer, the presence 
of Th17 cells was correlated with a prognosis 
improvement.30 
In our study, we demonstrated that stromal CD8+ 
TILs were significantly associated with the higher pCR 
rate. Upon exposure to foreign and tumor antigens, 
CD8+ T cells differentiate into CD8+ cytotoxic T 
lymphocytes (CTLs) and play a key role in the tumor-
specific cellular adaptive immune response. CD8+ 
CTLs induce apoptosis in tumor cells through death 
ligands and perforin/granzyme dependent pathways.31 
Studies are examining the role of CD8+ TILs in breast 
cancer. Denkert et al.20 showed that high mRNA 
expression of CD8A was a significant predictor of pCR 
in triple-negative and HER2-positive early breast 
cancer. Also, it was reported that a high level of CD8+ 
TILs in early breast cancer was an independent 
predictive factor of pCR,32 and was associated with a 
good prognosis.11,33 
We discovered that tumor infiltration by stromal 
CD20+ TILs was significantly higher in breast cancer 
patients who achieved a pCR than in those who did not 
achieve a pCR. B cells have antitumor effects through 
several pathways, including the presentation of tumor 
antigens and stimulation of anti-tumor responses of 
CD8+ and CD4+ T cells, secretion of anti-tumor auto-
antibodies that can promote cancer cell recognition        
and lysis, direct cytotoxic effect by granzyme B 
secretion.34 Previous studies have demonstrated that 
high stromal infiltration of B cells assessed by 
multiplexed quantitative immuno-fluorescence or by 
IHC was independently and significantly correlated 
with a high pCR rate in early breast cancer.9,10 Others 
have found out that the high expression of B cell-
related transcripts was associated with a favorable 




Our study demonstrated that the presence of 
stromal TILs and TILs subsets (CD3+, CD4+, CD8+ 
and CD20+ TILs) was significantly associated with an 
increased pCR rate in early TNBC. The level of TILs 
and TILs subsets in tumor stroma could be clinically 
beneficial in identifying patients with early TNBC who 
may benefit from NAC. In the future, it will be 
worthwhile to both integrate the predictive information 
obtained from stromal TILs and TILs subpopulations 
in post-NAC residual tumor specimens, and to 
determine the changes induced by NAC on stromal 
TILs and TILs subsets.  
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